NO20014127D0 - 5-HT1F agonister - Google Patents

5-HT1F agonister

Info

Publication number
NO20014127D0
NO20014127D0 NO20014127A NO20014127A NO20014127D0 NO 20014127 D0 NO20014127 D0 NO 20014127D0 NO 20014127 A NO20014127 A NO 20014127A NO 20014127 A NO20014127 A NO 20014127A NO 20014127 D0 NO20014127 D0 NO 20014127D0
Authority
NO
Norway
Prior art keywords
ht1f agonists
ht1f
agonists
Prior art date
Application number
NO20014127A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014127L (no
Inventor
Sandra Ann Filla
Brian Michael Mathes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20014127L publication Critical patent/NO20014127L/no
Publication of NO20014127D0 publication Critical patent/NO20014127D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20014127A 1999-02-26 2001-08-24 5-HT1F agonister NO20014127D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26
PCT/US2000/002505 WO2000050426A2 (en) 1999-02-26 2000-02-11 Furo[3, 2-b]pyridines as 5-ht1f agonists

Publications (2)

Publication Number Publication Date
NO20014127L NO20014127L (no) 2001-08-24
NO20014127D0 true NO20014127D0 (no) 2001-08-24

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014127A NO20014127D0 (no) 1999-02-26 2001-08-24 5-HT1F agonister

Country Status (21)

Country Link
EP (1) EP1155020B1 (tr)
JP (1) JP2002537398A (tr)
KR (1) KR20010102355A (tr)
AR (1) AR026856A1 (tr)
AT (1) ATE258935T1 (tr)
AU (1) AU3354000A (tr)
BR (1) BR0008479A (tr)
CA (1) CA2371784A1 (tr)
CO (1) CO5150234A1 (tr)
DE (1) DE60008073T2 (tr)
EA (1) EA200100918A1 (tr)
ES (1) ES2214256T3 (tr)
HU (1) HUP0200245A2 (tr)
ID (1) ID30056A (tr)
IL (1) IL144355A0 (tr)
NO (1) NO20014127D0 (tr)
PE (1) PE20001432A1 (tr)
PL (1) PL350864A1 (tr)
TR (1) TR200102436T2 (tr)
WO (1) WO2000050426A2 (tr)
ZA (1) ZA200106109B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004094380A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー ５−ｈｔ１ｆアゴニストとしての置換（４−アミノシクロヘキセン−１−イル）フェニルおよび（４−アミノシクロヘキセン−１−イル）ピリジニル化合物
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
IL144355A0 (en) 2002-05-23
CA2371784A1 (en) 2000-08-31
CO5150234A1 (es) 2002-04-29
KR20010102355A (ko) 2001-11-15
DE60008073T2 (de) 2004-08-05
NO20014127L (no) 2001-08-24
WO2000050426A3 (en) 2000-12-21
ES2214256T3 (es) 2004-09-16
HUP0200245A2 (en) 2002-06-29
ZA200106109B (en) 2002-07-25
EP1155020A2 (en) 2001-11-21
AU3354000A (en) 2000-09-14
PL350864A1 (en) 2003-02-10
EA200100918A1 (ru) 2002-02-28
ID30056A (id) 2001-11-01
JP2002537398A (ja) 2002-11-05
EP1155020B1 (en) 2004-02-04
ATE258935T1 (de) 2004-02-15
PE20001432A1 (es) 2000-12-18
TR200102436T2 (tr) 2002-06-21
AR026856A1 (es) 2003-03-05
DE60008073D1 (de) 2004-03-11
BR0008479A (pt) 2002-01-29
WO2000050426A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
DE69929895D1 (de) Prüfvorrichtung
NO20025115L (no) Muskarin agonister
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
DE60020036D1 (de) Ausgleichswellegehause
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO990431D0 (no) Golfk°llehode
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
NO20014127D0 (no) 5-HT1F agonister
DE60030066D1 (de) Prüfgerät
NO20022927D0 (no) Substituerte pyrrazoler
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE60018655D1 (de) Prüfvorrichtung
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
DK1200423T3 (da) Substituerede pehnyluraciler
ATA107599A (de) Heizwasserbereiter
DE10085167T1 (de) Gangumschalteinrichtung
ID27139A (id) Bertukol kusmargono

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application